GlassScriptPhysician profile
Patrick J O Brien
NPI 1356374219
$85,664.78
in general payments reported to CMS, 2019-2025
28 companies · $8,427 in 2025
The $8,427 reported for 2025 was more than what 98% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,464 · 2021: $25K · 2022: $22K · 2023: $11K · 2024: $4,683 · 2025: $8,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $2,234 · Travel and Lodging: $963 · Education: $15.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,825.00 |
| Food and Beverage | $2,234.07 |
| Travel and Lodging | $962.75 |
| Education | $15.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46,518.10 | 2019-2022 | |
| Abbvie INC. | $36,796.82 | 2022-2025 | |
| Medtronic, INC. | $476.86 | 2023-2025 | Synchromedii, Intellis Adaptivestim, Vectris Surescan |
| Janssen Pharmaceuticals, INC | $267.50 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $204.07 | 2023-2025 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $197.23 | 2019-2020 | |
| Ucb, INC. | $149.25 | 2023-2024 | Briviact, Nayzilam |
| Microtransponder, INC. | $130.90 | 2023 | |
| Neurocrine Biosciences, INC. | $122.45 | 2023-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $121.93 | 2019 | |
| Lundbeck LLC | $109.40 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $87.45 | 2019-2020 | |
| Neurelis, INC. | $85.41 | 2024 | Valtoco |
| Acadia Pharmaceuticals INC | $56.05 | 2019-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $47.93 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $40.41 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $30.43 | 2023 | Aptiom, Gemtesa |
| Ipsen Biopharmaceuticals, INC | $27.32 | 2024 | Dysport |
| Merz Pharmaceuticals, LLC | $24.39 | 2023 | Xeomin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.36 | 2020 | |
| Sk Life Science, INC. | $22.92 | 2023 | |
| Collegium Pharmaceutical, INC. | $21.07 | 2025 | Belbuca |
| Aimmune Therapeutics, INC. | $20.91 | 2024 | |
| Smith+Nephew, INC. | $18.57 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.69 | 2019 | |
| Boston Scientific Corporation | $15.46 | 2024 | Watchman Flx |
| Masimo Corporation | $15.05 | 2023 | Set and Rainbow Set, Emma and Isa |
| Lilly USA, LLC | $14.85 | 2023 | Trulicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick O Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.